Third Quarter 2024 Financial Results November 7, 2024 mode © 2024 Moderna, Inc. All rights reserved. Forward-looking statements and disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: Moderna's expected product sales in 2024 and trends informing Moderna's 2024 sales outlook; Moderna's ability to drive vaccination rates; Moderna's expectations regarding the 2025/2026 contractin ...

Moderna (MRNA) came out with quarterly earnings of $0.03 per share, beating the Zacks Consensus Estimate of a loss of $1.89 per share. This compares to loss of $1.39 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 101.59%. A quarter ago, it was expected that this biotechnology company would post a loss of $3.47 per share when it actually produced a loss of $3.33, delivering a surprise of 4.03%.Over the last four quarters, the ...

Moderna on Thursday posted a surprise profit for the third quarter, smashing Wall Street estimates, as its cost-cutting efforts took hold and sales of its Covid vaccine came in higher than expected. The biotech company posted a net income of $13 million, or 3 cents per share, for the third quarter. That compares with a net loss of $3.63 billion, or $9.53 cents per share, reported for the year-ago period.Moderna is slashing expenses, with a recently announced goal of achieving $1.1 billion in savings by 2027 ...

Exhibit 99.1 Moderna Reports Third Quarter 2024 Financial Results and Provides Business Updates Reports third quarter revenues of $1.9 billion, GAAP net income of $13 million and GAAP EPS of $0.03 Achieves year-to-date product sales of $2.2 billion; reiterates 2024 expected product sales of $3.0 to $3.5 billion Initiated dosing in two pivotal Phase 3 trials to assess efficacy of investigational mRNA vaccines against norovirus and influenza Announces expansion of its Executive Committee CAMBRIDGE, MA / ACCES ...

Moderna, Inc. MRNA will release earnings results for its third quarter, before the opening bell on Thursday, Nov. 7.Analysts expect the Cambridge, Massachusetts-based company to report a quarterly loss at $1.9 per share, versus a year-ago loss of $9.53 per share. Moderna projects to report revenue of $1.25 billion for the quarter, compared to $1.83 billion a year earlier, according to data from Benzinga Pro.On Oct. 28, On Monday, Merck & Co Inc MRK and Moderna announced the initiation of INTerpath-009, a pi ...

Moderna (MRNA) is set to report third-quarter 2024 earnings on Nov. 7, before the opening bell. The Zacks Consensus Estimate for sales and earnings is pegged at $1.25 billion and a loss of $1.91 per share, respectively. Both metrics indicate a significant decline from the year-ago levels.Estimates for Moderna’s 2024 loss per share have increased from $9.52 to $9.88 in the past 60 days. During the same period, estimates for 2025 loss per share have risen from $7.37 to $8.59. Image Source: Zacks Investment Re ...

Moderna (MRNA) closed the latest trading day at $55.22, indicating a +0.77% change from the previous session's end. This change outpaced the S&P 500's 0.16% gain on the day. Meanwhile, the Dow experienced a drop of 0.37%, and the technology-dominated Nasdaq saw an increase of 0.78%. Prior to today's trading, shares of the biotechnology company had lost 18% over the past month. This has lagged the Medical sector's loss of 4.09% and the S&P 500's gain of 1.67% in that time. Investors will be eagerly watching ...

Retirement is complicated and you only get once chance to do it right. Don't miss out because you didn't know what was out there.The Retirement Forum provides actionable ideals, a high-yield safe retirement portfolio, and macroeconomic outlooks, all to help you maximize your capital and your income. We search the entire market to help you maximize returns.Moderna, Inc. (NASDAQ: MRNA ) has seen steady weakness in its share price as demand for its COVID-19 vaccine has declined. The company has a $20 billion m ...

Despite giving the world one of the first and most widely used COVID-19 vaccines, shares of Moderna (MRNA) have lost significantly in the past couple of years due to declining sales amid low demand for the vaccine. In the past month, MRNA stock fell more than 20% after management provided an update on its business outlook for the next four years. It also announced plans to slash its research and development (R&D) budget during this period. In the past month, the stock has underperformed the industry's 2.3% ...

Dublin, Oct. 15, 2024 (GLOBE NEWSWIRE) -- The "mRNA Therapeutics Market Report 2024" report has been added to ResearchAndMarkets.com's offering. The mRNA therapeutics market size has grown steadily in recent years. It will grow from $33.5 billion in 2023 to $34.76 billion in 2024 at a compound annual growth rate (CAGR) of 3.8%. The mRNA therapeutics market size is expected to see steady growth in the next few years. It will grow to $40.69 billion in 2028 at a compound annual growth rate (CAGR) of 4%. During ...